This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Faculty:
Ahmad Masri, MD, MS
Associate Professor of Medicine
Cardiology
Oregon Health & Science University
Portland, OR
Research: Attralus, Cytokinetics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Pfizer
Consulting Fees: Akros, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, AstraZeneca, Attralus, Avidity Biosciences, BioMarin Pharmaceutical, BridgeBio Pharma, Bristol Myers Squibb, Cytokinetics, Edgewise Therapeutics, Haya Therapeutics, Ionis Pharmaceuticals, Lexeo Therapeutics, Lexicon Pharmaceuticals, Neurimmune, Pfizer, Prothena, Rocket Pharmaceuticals, Tenaya Therapeutics
Michael Nassif, MD, MSc
Associate Professor of Medicine
Cardiology
Saint Luke’s Heart Institute
Kansas City, MO
Research: Bristol Myers Squibb, CytokineticsAnjali Tiku Owens, MD
Director, Center for Inherited Cardiac Disease
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PAResearch: BMS
Consulting Fees: Alexion, Avidity, Bayer, BMS, Braveheart, BridgeBio, Cytokinetics, Edgewise, Imbria, Kardigan, Lexeo, Stealth, TenayaReviewers/Content Planners/Authors:
- Cindy Davidson has no relevant relationships to disclose.
- Katie Sheridan, PhD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Discuss the persistent unmet clinical needs in patients with obstructive hypertrophic cardiomyopathy (oHCM)
- Analyze the impact of the mechanisms of action and pharmacokinetic and pharmacodynamic properties of cardiac myosin inhibitors on clinical decision-making in patients with oHCM
- Interpret the efficacy and safety profiles of cardiac myosin inhibitors based on pivotal phase 3 clinical trials in patients with oHCM
- Develop individualized, evidence-based treatment strategies, integrating myosin inhibition to optimize outcomes and enhance the quality of life for patients with oHCM
Target Audience
This activity has been designed to meet the educational needs of cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with obstructive hypertrophic cardiomyopathy.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 contact hour(s)/0.10 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-26-028-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit(s). Approval is valid until 3/26/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
This activity is supported by an independent educational grant from Cytokinetics, Incorporated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.
